• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Exact Sciences Corporation

    10/10/23 1:51:48 PM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email
    SC 13G 1 EXACT_SCIENCES_CORPORATION.htm FILING EXACT SCIENCES CORPORATION Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     
    EXACT SCIENCES CORPORATION 

    (Name of Issuer)
     
    Common Stock, $0.01 par value per share

    (Title of Class of Securities)
     
    30063P105

    (CUSIP Number)
     
    September 29, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  30063P105            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      17,373,578
         
    6   SHARED VOTING POWER
       
      14,649
         
    7   SOLE DISPOSITIVE POWER
       
      18,638,179
         
    8   SHARED DISPOSITIVE POWER
       
      10,884
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      18,652,296
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      10.3 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    EXACT SCIENCES CORPORATION


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    5505 Endeavor Lane,
    Madison WI, 53719


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.01 par value per share


     
    (e)
    CUSIP Number
     
     
    30063P105


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 18,652,296


     
    (b)
    Percent of class: 10.3 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 17,373,578


     
    (ii)
    Shared power to vote or to direct the vote: 14,649


     
    (iii)
    Sole power to dispose or to direct the disposition of: 18,638,179


     
    (iv)
    Shared power to dispose or to direct the disposition of: 10,884


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Trust Company of Delaware
    J.P. Morgan Securities LLC
    JPMorgan Chase Bank, National Association
    JPMorgan Asset Management (Asia Pacific) Limited
    JPMorgan Asset Management (UK) Limited
    J.P. MORGAN SE
    J.P. Morgan (Suisse) SA
    J.P. Morgan Investment Management Inc.
    JPMorgan Asset Management (Japan) Limited
    55I, LLC
    First Republic Investment Management, Inc
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: October 10, 2023
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $EXAS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    1/2/2024$91.00Hold → Buy
    The Benchmark Company
    12/14/2023$90.00Buy
    Guggenheim
    More analyst ratings

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 5:23:44 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 4:56:30 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 4:55:27 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GM, Screening Orville Jacob A sold $375,000 worth of shares (5,000 units at $75.00), decreasing direct ownership by 18% to 23,237 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/21/25 5:30:06 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SVP, General Counsel & Sec Herriott James sold $70,000 worth of shares (1,000 units at $70.00), decreasing direct ownership by 8% to 11,585 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/21/25 5:30:03 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SVP, General Counsel & Sec Herriott James sold $105,120 worth of shares (1,500 units at $70.08), decreasing direct ownership by 11% to 12,585 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/6/25 5:29:37 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Exact Sciences with a new price target

    Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

    4/10/25 12:41:36 PM ET
    $EXAS
    Medical Specialities
    Health Care

    RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

    RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

    3/13/25 7:36:02 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Barclays initiated coverage on Exact Sciences with a new price target

    Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00

    1/23/25 7:42:29 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening Tests

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its previously announced license agreement with Freenome. Under the agreement, the Company acquired exclusive rights in the United States to Freenome's blood-based colorectal cancer (CRC) screening tests. The exclusive license expands Exact Science's leadership in cancer screening by adding blood-based CRC screening options to its portfolio. Exclusivity remains subject to Freenome's test receiving first-line FDA approval. 2025 Outlook As stated on the recent third qua

    11/10/25 7:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    10/7/24 11:37:08 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    2/6/25 8:30:00 AM ET
    $EXAS
    $GE
    $GMED
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology

    $EXAS
    Financials

    Live finance-specific insights

    View All

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Exact Sciences Announces Third Quarter 2025 Results

    Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively Generated record cash from operations and free cash flow Launched Cancerguard®, the company's multi-cancer early detection test, for patients in the United States Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer scree

    11/3/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Schedules Third Quarter 2025 Earnings Call

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: Monday, November 3, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers

    10/8/25 7:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care